← Back to Search

Intravenous Ketamine for Major Depressive Disorder

Phase 1 & 2
Waitlist Available
Research Sponsored by Rebecca Price
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up infusion +24 hours (1 day)
Awards & highlights

Study Summary

This trial will study how well a single dose of ketamine works to improve depression symptoms by tracking the functioning of potential neurobiological targets over time.

Eligible Conditions
  • Major Depressive Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~infusion +24 hours (1 day)
This trial's timeline: 3 weeks for screening, Varies for treatment, and infusion +24 hours (1 day) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
fMRI resting state connectivity
Secondary outcome measures
Hamilton Depression Rating Scale
Mental Depression
Quick Inventory of Depressive Symptoms
Other outcome measures
Dual probe video task

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intravenous KetamineExperimental Treatment1 Intervention
Open-label ketamine infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Rebecca PriceLead Sponsor
6 Previous Clinical Trials
653 Total Patients Enrolled

Media Library

Intravenous Ketamine Clinical Trial Eligibility Overview. Trial Name: NCT04916548 — Phase 1 & 2
Major Depressive Disorder Research Study Groups: Intravenous Ketamine
Major Depressive Disorder Clinical Trial 2023: Intravenous Ketamine Highlights & Side Effects. Trial Name: NCT04916548 — Phase 1 & 2
Intravenous Ketamine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04916548 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial admitting geriatric individuals as participants?

"This trial is open to people of legal age and under 60 years old."

Answered by AI

Is it possible for me to participate in this clinical assessment?

"To qualify for this medical trial, prospective participants must be of legal age with a diagnosis of melancholia. A total of 20 individuals can join the research initiative."

Answered by AI

What is the capacity of this trial in terms of participant recruitment?

"Affirmative. On clinicaltrials.gov, the information states that this medical study is recruiting patients. It was first announced on September 16th 2021 with its last update occuring in August 2022 and seeks to enrol 20 subjects from a single site."

Answered by AI

Are there any vacancies remaining for participants in this trial?

"Clinicaltrials.gov indicates that this medical research is actively recruiting participants, having been initially posted on September 16th 2021 and revised most recently on August 1st 2022."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Pennsylvania
New York
How old are they?
18 - 65
What site did they apply to?
Western Psychiatric Institute and Clinic
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+
Recent research and studies
clinicaltrials.govStudy
Repeated Neurocognitive Measurements in Depressed Patients
Rebecca Price 2021. "Repeated Neurocognitive Measurements in Depressed Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04916548.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top